Here are the DEF 14A proxy statements from Boundless Bio, Inc. (BOLD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BOLD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BOLD filings page.
Boundless Bio, Inc. is holding its 2026 Annual Meeting of Stockholders as a virtual-only audio webcast on June 15, 2026 at 11:00 a.m. Pacific Time. Stockholders are being asked to elect James Christensen, Ph.D. and Jennifer Lew as Class II directors to serve until the 2029 annual meeting and to ratify KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.
The record date is April 20, 2026, when 22,418,751 shares of common stock were outstanding and entitled to vote, with one vote per share. The proxy explains how stockholders of record and beneficial owners can register, attend online, vote in advance or during the meeting, and change previously submitted votes. It also details board structure, independence, executive officers, and 2025 executive compensation, including salary, bonus, and stock option awards, along with the company’s severance and change in control plan for senior management and its non-employee director compensation program.